Characterization of the Interleukin-17 Effect on Articular Cartilage in a Translational Model. An Explorative Study

CURRENT STATUS: ACCEPTED

BMC Rheumatology  BMC Series

Dovile Sinkeviciute
Nordic Bioscience
dsi@nordicbio.com Corresponding Author
ORCID: https://orcid.org/0000-0003-4275-388X

Anders Aspberg
Lunds universitet Medicinska fakulteten

Yi He
Nordic Bioscience

Anne-Christine Bay-Jensen
Nordic Bioscience

Patrik Önnerfjord
Lunds universitet Medicinska fakulteten

DOI:
10.21203/rs.2.14893/v3

SUBJECT AREAS
Rheumatology

KEYWORDS
osteoarthritis, inflammation, interleukin-17
Abstract

Background Osteoarthritis (OA) is a progressive, chronic disease characterized by articular cartilage destruction. The pro-inflammatory cytokine IL-17 levels have been reported elevated in serum and synovial fluid of OA patients and correlated with increased cartilage defects and bone remodeling. The aim of this study was to characterize an IL-17-mediated articular cartilage degradation ex-vivo model and to investigate IL-17 effect on cartilage extracellular matrix protein turnover. Methods Full-depth bovine femoral condyle articular cartilage explants were cultured in serum-free medium for three weeks in the absence, or presence of cytokines: IL-17A (100 ng/ml or 25 ng/ml), or 10 ng OSM combined with 20 ng/ml TNFα (O+T). RNA isolation and PCR analysis were performed on tissue lysates to confirm IL-17 receptor expression. GAG and ECM-turnover biomarker release into conditioned media was assessed with dimethyl methylene blue and ELISA assays, respectively. Gelatin zymography was used for matrix metalloproteinase (MMP) 2 and MMP9 activity assessment in conditioned media, and shotgun LC-MS/MS for identification and label-free quantification of proteins and protein fragments in conditioned media. Western blotting was used to validate MS results. Results IL-17RA mRNA was expressed in bovine articular cartilage and the treatment with IL-17A did not interfere with metabolic activity of the model. IL-17A induced cartilage breakdown; conditioned media GAG levels were 3.6-fold-elevated compared to untreated. IL-17A 100 ng/ml induced ADAMTS-mediated aggrecan degradation fragment release (14-fold increase compared to untreated) and MMP-mediated type II collagen fragment release (6-fold-change compared to untreated). MS data analysis revealed 16 differentially expressed proteins in IL-17A conditioned media compared to untreated. CHI3L1 upregulation in conditioned media in response to IL-17A was confirmed by Western blotting. Conclusions We showed that IL-17A has cartilage modulating potential. It induces collagen and aggrecan degradation indicating an upregulation of MMPs. This was confirmed by zymography and mass spectrometry data. We also showed that the expression of other cytokines is induced by IL-17A, which provide further insight to the pathways that are active in response to IL-17A. This exploratory study confirms that IL-17A may play a role in cartilage pathology and that the applied model may be a good tool to further investigate it.
Background
Articular cartilage – an aneural, avascular and alymphatic connective tissue that can withstand compressive load – provides a low friction gliding surface, facilitating synovial joint articulation (1, 2). It is composed of chondrocytes (1-5% of the cartilage tissue volume) and a dense extracellular matrix (ECM), which primarily consists of water (up to 80% of wet cartilage weight), proteoglycans and collagens (1). The ECM mainly provides the biomechanical properties and function of cartilage while chondrocytes regulate cartilage homeostasis and, thus, are key for its development, maintenance and repair (1, 2).

Osteoarthritis (OA) is a degenerative joint disease, characterized by progressive articular cartilage destruction, subchondral bone remodeling and occasional synovial inflammation (3). It is the most common joint disease worldwide and one of the most frequent health problems experienced by middle aged and older people (3, 4). It affects women more frequently than men, is more common in the developed world and has a negative impact on patient well-being (3, 5, 6). Obesity, gender, age, genetics, diet, joint injury, abnormal joint loading and joint malalignment are risk factors for OA (3, 7).

OA is a heterogeneous disease thought to be composed of multiple phenotypes, each with a different underlying driver, e.g.: age, cartilage damage, metabolic dysregulation, subchondral bone remodeling, and inflammation (4). In a healthy joint a fine balance of cartilage synthesis and degradation is maintained, but in OA cartilage the homeostasis is disrupted by mechanisms driven by a combination of biological mediators and biomechanical stimuli (2). This leads to over-active inflammatory, degradation and synthesis processes, which are mediated by cytokines, matrix-degrading proteinases and growth factors (2). Inflammatory cytokines are among the most important and best documented factors participating in the pathogenesis of joint disease and cartilage degradation (8). They contribute to the destruction of articular cartilage via 1) decreasing the synthesis of key ECM components, 2) increasing the release of proteolytic enzymes that degrade articular cartilage, such as various MMP (matrix metalloproteinase) and ADAMTS (A Disintegrin and Metalloproteinase with Thrombospondin motifs) enzymes, and 3) release of inflammatory PGE$_2$
(prostaglandins), COX-2 (cyclooxygenase 2), nitric oxide (NO) and free radicals into the intraarticular space (2, 9). It is now generally accepted that tumor necrosis factor alpha (TNFα) is one of the key cytokines in the process of chronic joint inflammation and subsequent changes in cartilage and bone; its serum and synovial fluid levels correlate positively with disease scores in both OA and RA patients (8). Anti-TNF therapy in RA is already FDA and EMA approved and reportedly shows chondroprotective effects (8). Furthermore, TNFα can synergize with other cytokines, such as interleukin-6 (IL-6), interleukin-17 (IL-17), or oncostatin M (OSM) to further promote matrix turnover and cartilage destruction (10-13).

The IL-17 pro-inflammatory cytokine family has only more recently gained attention in the OA field (14). The family consists of six ligands: IL-17A, IL-17B, IL-17C, IL-17D, IL-17E (also known as IL-25), and IL-17F, and five corresponding receptors (IL-17RA, IL-17RB, IL-17RC, IL-17RD, IL-17RE)(15). IL-17A is the most extensively studied of the family and is often referred to as simply “IL-17”. IL-17A signals through a IL-17RA/IL-17RC heterodimeric receptor complex as a homodimer or a heterodimer with IL-17F; the receptor activation leads to recruitment of intermediate adaptor protein Act1, and activation of several signaling pathways: the canonical nuclear factor kappa light chain enhancer of activated B cells (NFκB) pathway, the mitogen-activated protein kinase (MAPK) signaling pathway, as well as C/EBPs, JAK-PI3K and JAK-STAT pathways (16-19). As a result, IL-17 mediates angiogenesis, recruitment of inflammatory cells, and induction of proinflammatory mediator release (16). IL-17 receptor is expressed in vivo in chondrocytes from different arthropathies (RA, OA, and seronegative spondyloarthropathies) (20), and IL-17 is implicated in multiple joint pathologies, such as psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis (21, 22), and drugs targeting IL-17 have been approved for treatment of psoriatic arthritis (23). In OA patients, elevated serum and synovial fluid levels of IL-17 were reported to show a positive correlation with radiographic features of the disease (24-29). The physiological levels in healthy and OA subjects in these studies were in the order of 1-10 pg/ml in both serum and synovial fluid. Furthermore, in certain populations polymorphisms in the IL-17A gene may correlate with susceptibility to OA (30).

There are currently no clinically approved disease-modifying drug (DMOAD) treatments for OA. The
clinical trial failure rate for new drugs is relatively high, due to, in part, the heterogeneity of the OA patient population (4, 31), thus a better understanding of articular cartilage biology, particularly in relation to its degradation would facilitate a better subtyping of patients and benefit the screening of novel drug candidates.

Kjelgaard-Petersen et al. (2018) have previously shown that full-depth bovine articular cartilage explants (BEX) treated with oncostatin M in combination with TNFα (O+T) were a reliable translational model for rheumatoid arthritis by successfully back-translating the serological biomarker results from a phase III clinical study (OSKIRA-1) (32). Proteomic technologies allow for a large-scale unbiased investigation, making it possible to identify factors involved in joint disease progression and build a library of mediators: previous studies have revealed numerous cytokines, proteases, and matrix fragments in serum, synovial fluid, and articular cartilage of OA patients (33-36). Therefore, adapting the BEX model for studying IL-17-mediated articular cartilage changes and combining it with proteomics could contribute to a better understanding of molecular events involved in IL-17-mediated cartilage turnover and identification of its biomarkers. The ability to better identify IL-17-mediated processes in cartilage would benefit both clinical studies and the clinic, through better patient selection and better matching of the available anti-IL-17 therapies to the patients, respectively. In this pilot study we aim to characterize a model of IL-17 mediated knee cartilage destruction and to investigate IL-17 effects on articular cartilage protein turnover by using biomarker assays and proteomics for analysis of proteins released into explant media, while benchmarking the effect to O+T.

Methods

Materials and buffers

Bovine knees were obtained from the local abattoir (Harald Hansens Eftf. I/S, Denmark). Biopsy punchers were purchased from Scandidact (cat#MTP-33-32). Dulbecco’s Modified Eagle medium (DMEM)/F12-GlutaMAX™ purchased from Thermo Fisher (cat#31331-093), together with Penicillin and Streptomycin (P/S) (cat#4333). The cytokines OSM (cat#O9635, Sigma-Aldrich), TNFα (R&D Systems, cat#210-TA), IL-17A (R&D Systems, cat#7955-IL) were reconstituted in 0.1 % bovine serum albumin
(BSA) and further diluted in culture medium. All chemicals were purchased from Sigma-Aldrich or Merck unless stated otherwise.

**Full-depth bovine articular cartilage explant tissue culture**

Intact healthy stifle joints (i.e. with no perforation of the synovial capsule) from <2-year-old cattle were used within 48 hours after slaughter. After dissection and exposing the articular cartilage under sterile conditions, full-depth, 3 mm-in-diameter bovine cartilage explants (BEX) were punched out from the medial and lateral condyle and released from the subchondral bone with a sharp scalpel. One explant per well were placed in 96-well plates and washed five times in explant culture medium (DMEM+Glutamax/F12 (1:1) + 1 % Penicillin + 1 % Streptomycin). Plates were pre-incubated overnight at 37°C, 5 % CO₂, ambient oxygen level for explants to equilibrate. Next day, explant metabolic activity was assessed using the alamarBlue (resazurin) metabolic assay (37) and fresh media containing treatments (10 ng/ml OSM in combination with 20 ng/ml TNFα; 100 ng/ml IL-17A; 25 ng/ml IL-17A or media without any treatment were added to an equal number of explants. Previous explant studies have used IL-17 levels in the range of 0.4-100 ng/ml (38-40). Based on preliminary cartilage explant experiments assessing collagenolytic activity in response to IL-17A (Supplementary figure 1), we selected our upper level to be 100ng/ml with the additional dose of 25ng/ml for comparison in our model. Both these concentrations are higher than reported physiological levels in serum and synovial fluid. However, in order to keep the experiments within a reasonable time frame this compromise was made in this exploratory study. Explants, with or without stimuli, were cultured at 37°C, 5 % CO₂, ambient oxygen level for 21 days with media changes and conditioned media harvests performed three times a week, and metabolic activity assessed every seven days. Conditioned media from two animals (six technical replicates - explants - per condition, per animal) were selected for biomarker analysis. For proteomics analysis, conditioned media from additional two animals (two technical replicates - explants - per condition, per animal) were used.

**Explant metabolic activity assessment using alamarBlue assay**

Two hundred μl of 10 % alamarBlue (Thermo Fisher Scientific, cat#DAL1100) in BEX culture media
solution was added to each well containing an explant and 4 empty wells for background. The 96-well plates were incubated for 3 hours at 37°C, 5 % CO₂, after which 160 μl of alamar media was transferred to a black 96-well plate and read in a fluorimeter (Ex: 540 nm, Em: 590 nm, SpectraMax M5, Molecular Devices). The metabolic activity was measured in a total of 24 explants per each treatment group: 6 explants for each treatment group per animal; tissue from 4 animals.

**PCR for IL-17R expression verification**

Healthy, full-depth bovine femoral condyle articular cartilage (2.5 g) from two individual animals was snap-frozen and pulverized using a mortar and pestle in liquid nitrogen. Total RNA was extracted using RNAqueous Micro Kit (Thermo Fisher Scientific, cat#AM1912) according to the manufacturer’s instructions. Briefly, 4 ml of Lysis/Binding solution was added to 400 mg of pulverized cartilage and the lysate was homogenized using a rotor-stator homogenizer and centrifuged to 3 min at 16,000 x g to remove debris. The supernatant was mixed thoroughly with an equal volume of 64 % ethanol and loaded onto Filter Cartridges (700 μl per cartridge). After washing, RNA from each cartridge was eluted using 40 μl + 10 μl of the kit’s elution solution. The eluates were combined, and the RNA amount was spectrophotometrically determined (Nanodrop2000, Thermo Fisher Scientific). cDNA synthesis was performed with the Maxima First Strand cDNA Synthesis Kit for RT-qPCR (Thermo Fisher Scientific, cat#K1641), using 50 ng total RNA in a total volume of 20 μl and incubated at: 25°C (10 min), 50°C (15 min) and 85°C (5 min). IL-17 receptor amplification was performed using Dream Taq Green PCR kit, with 0.5 ng (assuming 1:1 conversion from RNA) template cDNA and 200 nM (each) primers for IL-17RA (bIL17RA_f1: GCCATTCCCAGGAGCTAAA, bIL17RA_r1: CCACTGACGACCAACA, product size: 459 bp), IL-17RB (bIL17RB_f1: ATCACCTTGGGCACATCA, bIL-17RB_r1: AAAACGTCCATTGCGCACCAC, product size: 444 bp), IL-17RC (bIL17RC_f2: TCTCTGGGAATTGCGTGTGC, bIL17RC_r2: AGGATCTTCCGTACACCCT, product size: 178 bp), or IL-17RE (bIL17RE_f1: GGAGCCACACTGTAGCAGCTCT, bIL17RE_r1: ACATACCACCTCTGACTCT, product size: 307 bp). The amplification was performed in a SimpliAmp PCR apparatus (Applied Biosystems) and the cycle conditions were: 95°C (3 min), 40 cycles of 95°C
(30 s), 55°C (30 s), 72°C (1 min), followed by 72°C (10 min). The PCR products were separated on a 2% agarose gel (containing ethidium bromide) by electrophoresis and visualized by UV light in a ChemiDoc MP System (BioRad). PCR product bands were detected, and size estimated by ImageLab 6.0.1 software (BioRad). The gel image was exported as a TIFF file, cropped and annotated using Affinity Design 1.7.

**Sulfated glycosaminoglycan (GAG) release measurement using a DMMB assay**

The 1,9-dimethylmethylene blue (DMMB, Sigma-Aldrich, cat#341088) assay with chondroitin sulfate (Sigma, cat#C9819) as standard was used to measure the concentration of released GAGs from the cartilage explants in the culture medium (41, 42). The GAG content was determined by adding 250 μl DMMB solution (0.05 mM DMMB, 41 mM NaCl, 45 mM glycine and pH = 3.0) to 20 μl supernatant sample in a 96-well plate and immediately measuring the colorimetric change using a plate reader (SpectraMax M5, Molecular Devices) at 570 nm.

**Histological analysis**

To visualize proteoglycans in the tissue, cartilage explants were fixed on the last day of culture using 4 % phosphate-buffered formalin (pH 7.0), dehydrated with an automated tissue-processing apparatus (Sakura Tissue Tek VIP 5) and embedded in paraffin. The embedded tissue was cut to 5-micron thickness with the microtome knife angled at 9-10 degrees. The sections were collected on Superfrost+ glass slides (Thermo Scientific, cat# J1800AMNT), stained with safranin O/fast green (Brunschwig Chemie) and mounted with Eukitt mounting medium (Sigma-Aldrich, cat# 03989). The slides were analyzed on a Zeiss Axioplan-2 imaging system (Carl Zeiss). The samples were viewed through a 10x objective and images captured with an AxioCam HR camera using AxioVision 4.2 (Carl Zeiss) software.

**Gelatin zymography**

Pre-cast Novex™ Zymogram Plus Gels (Thermo Fisher Scientific, cat#ZY00100BOX), 10X Tris-Glycine SDS Running Buffer (Thermo Fisher Scientific, cat#LC2675), 10X Novex™ Zymogram Renaturing Buffer (Thermo Fisher Scientific, cat#LC2670) and 10X Novex™ Zymogram Developing Buffer (Thermo Fisher Scientific, cat#LC2671) and the XCell SureLock Mini-Cell (Thermo Fisher Scientific) gel
running system was used for gelatin zymography, following the manufacturer’s instructions. Briefly, 15 μl of sample was diluted 1:1 in 2X Tris-Glycine SDS Sample Buffer. 20 μl of samples were loaded onto the 1.0 mm, 10-well gelatin gel, immersed in 1X Tris-Glycine SDS Running Buffer and run for 105 minutes at constant 125 V. The gel was renatured and equilibrated as recommended and developed in 1X Zymogram Developing Buffer at 37°C for 24 hours. The gel was stained with SimplyBlue Safestain (Thermo Fisher Scientific, cat#LC6060) using the high-sensitivity protocol.

**Western blotting**

Pooled conditioned media (from days 10, 14, 19 and 21) was diluted in NuPAGE 4X LDS Sample Buffer (Thermo Fisher Scientific, cat#NP0007), heated at 70°C for 10 minutes, then 20 μl was loaded onto a pre-cast NuPAGE 4-12% Bis-Tris 1.0 mm mini gel (Thermo Fisher Scientific, cat#NP0321BOX). The gel was run at 50V for 30 minutes followed by 70 V for 1.5 hour in 1X MES SDS buffer (Thermo Fisher Scientific, cat#NP0002). The protein transfer to nitrocellulose membrane was performed using P3 program on iBlot 2 Dry Blotting System (Thermo Fisher Scientific) according to manufacturer’s instructions. After blocking non-specific binding for 1 hour at room temperature with 5% BSA in Tris-buffered saline, 0.1% Tween 20 (TBST), the membrane was incubated with primary antibody against CHI3L1 (1:500, rabbit anti-human CHI3L1, Abcam, cat#ab180569) in 5% BSA TBST. After washing, the membrane was incubated with secondary antibody (1:50000, Jackson ImmunoResearch, cat#111-035-003) in 5% BSA TBST for 1 hour at room temperature. Signals were visualized with SuperSignal West Femto chemiluminescence kit (Thermo Fisher Scientific, cat#34094) on ChemiDoc MP System (BioRad). The blot image was exported as a TIFF file, cropped and annotated using Affinity Design 1.7.

**Cartilage degradation biomarker measurements**

Cartilage degradation was measured using three protein neo-epitope biomarker enzyme-linked immunosorbent assays (ELISAs): C2M (Nordic Bioscience, cat#1100), C3M (Nordic Bioscience, cat#1200) and exAGNx1 (Nordic Bioscience, in-house kit), using a method described previously (43-45). Briefly, 96-well streptavidin-coated microtiter plates were coated for 30 minutes at 20°C with the respective biotin-labelled neo-epitope peptides. Unbound peptide was washed off and 20 μL
samples/standards were added, followed by 100 μl/well of peroxidase-labeled (C2M, C3M) or unlabeled (exAGNx1) monoclonal antibody in an assay-specific buffer. The plates were incubated either overnight at 4°C (C2M), for 3 hours (exAGNx1) at 20°C, or for 1 hour (C3M) at 20°C. ExAGNx1 was additionally incubated for 1 hour with a secondary anti-mouse horseradish peroxidase (HRP) labelled antibody after the 3-hour incubation with the primary antibody. The plates were washed and developed using 3,3′,5,5′-Tetramethylbenzidine (TMB) and the reaction was stopped with sulfuric acid after 15 minutes. All assays were read on a standard plate reader (SpectraMax M5, Molecular Devices) at 450 nm with reference at 650 nm and calibration curves were plotted using a four-parametric mathematical fit model.

**Sample processing and mass spectrometry for analysis of protein release from articular cartilage**

Fifty μl of conditioned culture medium from different time points (days 10, 14, 19 and 21 of culture) was reduced by 4 mM dithiothreitol for 30 min at 56 °C, alkylated by 16 mM iodoacetamide for 60 min in the dark at room temperature, precipitated with ethanol and digested by 0.25 μg trypsin gold (Promega, cat#V5280) in 100 μl 0.1 M ammonium bicarbonate (AMBIC) buffer pH 7.8 for 16 hours on a shaker at 37 °C. After addition of 100 μl 1 M NaCl with 1% formic acid to the digests, these were run through 30 kDa filters (PALL Life Sciences, cat#OD030C34) to remove GAGs and desalted with reversed-phase Vydac UltraMicro Spin C18 columns (Harvard Apparatus, cat#74-7206) according to the manufacturer’s instructions. Non-targeted mass spectrometry analysis was performed on a quadrupole Orbitrap benchtop mass spectrometer, QExactive, (Thermo Scientific) equipped with an Easy nano-LC 1000 system (ThermoFisher Scientific). Separation was performed on 75 μm × 25 cm, Acclaim Pepmap™ RSLC C18 capillary columns packed with 2 μm particles (ThermoFisher Scientific). A spray voltage of + 2000 V was used with a heated ion transfer setting of 275 °C for desolvation. The on-line reversed-phase separation was performed using a flow rate of 300 nl/min and a linear binary gradient 85 min was used. The gradient started with 3% solvent B for 4 min, then going to 35% solvent B in 64 min, after which it goes to 45% solvent B in 5 min. Finally, the organic solvent concentration was increased up to 90% in 5 min and kept at 90% for 7 min. An MS scan (400–1200
m/z) was recorded in the Orbitrap mass analyzer set at a resolution of 70,000 at 200 m/z, $1 \times 10^6$ automatic gain control (AGC) target and 100 ms maximum ion injection time (46). The MS was followed by data-dependent collision-induced dissociation MS/MS scans at a resolution of 17,500 on the 15 most intense multiply charged ions at $2 \times 10^4$ intensity threshold, 2 m/z isolation width and dynamic exclusion enabled for 30 s.

**MS data analysis**

Identification from discovery data was performed using the *Bos taurus* proteome (UniProt proteome ID UP000009136, n23868, downloaded 08/06/2015) with Proteome Discoverer 2.3 software (ThermoFisher Scientific). The processing workflow consisted of the following nodes: Spectrum Selector for spectra pre-processing (precursor mass range: 350–5000 Da; S/N Threshold: 1.5), Sequest-HT search engine (Protein Database: see above; Enzyme: Trypsin; Max. missed cleavage sites: 2; Peptide length range 6–144 amino acids; Precursor mass tolerance: 10 ppm; Fragment mass tolerance: 0.02 Da; Static modification: cysteine carbamidomethylation; and Percolator for peptide validation (FDR < 1% based on peptide q-value). Results were filtered to keep only the Master protein with at least one unique peptide, and protein grouping was allowed according to the parsimony principle. For label-free quantification (LFQ), the sum of the top 3 peptides for each protein was taken to reflect the intensity of the protein. Peptide intensities were quantified using a proprietary algorithm developed in Proteome Discoverer 2.3 (ThermoFisher Scientific).

**Statistical analysis and data visualization**

Biomarker measurements below Lower Limit of Measurement Range (LLMR) were imputed as the LLMR of the individual biomarker. Biomarker measurements above Upper Limit of Measurement Range (ULMR) were imputed as the ULMR of the individual biomarker and not re-measured due low remaining sample volume. The release of GAGs and biomarkers over time was quantified by plotting the concentration in the medium against time in culture and calculating the area under the curve (AUC) using GraphPad Prism 7 for each BEX explant. For biomarker AUCs the baseline was set at the LLMR for the individual biomarker. The distribution of the AUC values was tested using R (version
3.4.0) by plotting histograms and quantile-quantile (Q-Q) plots. Since the GAG and biomarker data did not follow a Gaussian distribution a non-parametric Kruskal-Wallis with Dunn’s multiple comparison test was used to test for differences of the AUCs of GAG, AGNx1, C2M and C3M between the treatments, where \( p < 0.05 \) was considered significant.

The proteomics data was exported from Proteome Discoverer for statistical data analysis and visualization using R (version 3.5.1). The individual explant (technical replicate) LFQ values were log2-transformed and averaged, giving mean log2 value per treatment per timepoint for each animal. The data was then filtered so that only proteins present in both animals in both the untreated and the IL-17-treated samples were retained. Then, AUC was calculated to obtain a single value per the treatment group (untreated or IL-17A) within each animal, and the differences between untreated and IL-17 groups were compared for each protein using a reproducibility-optimized test statistic (ROTS) from ROTS package (47-50) \( (B = 1000) \), with adjusted \( p \)-value of \(<0.05\) and FDR of \(<0.05\) considered significant.

**Results**

**IL-17 receptor mRNA is expressed in bovine full-depth articular cartilage**

In order to confirm that our model system can respond to IL-17 stimulus, IL-17A receptor expression was verified in freshly harvested full-depth bovine stifle joint articular cartilage tissue biopsies by PCR and 2% agarose gel electrophoresis. An approximately 445 bp PCR product corresponding to IL-17RA (calculated size: 459 bp) – the receptor for IL-17A – was observed in both animals analyzed (Fig.1). Additionally, weaker PCR products were observed at approximately 185 bp for IL-17RC (calculated size: 178 bp) and at approximately 350 bp for IL-17RD (calculated size: 364 or 433 bp, dependent on splicing). Thus, at least IL-17RA and C are expressed in bovine articular cartilage, while IL-17RD expression appears variable.

**Treatment with IL-17A does not interfere with the metabolic activity of the model**

Next, to verify that our explant system remains viable throughout the three-week tissue culture period and, thus, that any observed changes to protein release into conditioned media are not due to tissue death, the metabolic activity of explants was assessed every 7\(^{th}\) day of the culture period using
a commercial resazurin-based metabolic assay. There was no statistically significant reduction in metabolic activity over three weeks tissue culture period between the cytokine-treated explants and the untreated explants (Fig.2A and B).

**IL-17A induces extracellular matrix breakdown in the explant model**

The ability of IL-17 to induce degradation of glycosaminoglycans has been previously described in other ex-vivo models (39, 40). In order to verify this in our model, sulfated GAG release into conditioned media was measured over the three week-long culture period by a DMMB colorimetric assay and visualized by safranin O/fast green F histological staining of explant tissue section. IL-17A at both lower (25 ng/ml) and higher (100 ng/ml) concentrations induced GAG release from bovine knee full-depth articular cartilage explants in a time-dependent manner, as did O+T, which was used in the model as a positive control of cartilage catabolic responsiveness (Fig.3A). Compared to the untreated group the overall conditioned media GAG levels were, on average, 3.67-fold higher in the IL-17A[100ng/ml] group, 3.65-fold higher in in the IL-17A[25ng/ml group] and 3.4-fold higher in the O+T group (Fig.3B). In the explant tissue, in contrast, very little proteoglycan (safranin O) staining remained in any of the three cytokine-treated explant groups at day 21, whereas a normal cartilage structure was preserved in untreated explants (Fig.3C-D).

To further investigate the effect of IL-17A on ECM turnover of explants, and to confirm the usefulness of serological ECM turnover biomarkers in our model, degradation fragments of major cartilage structural proteins were measured by competitive sandwich ELISA. The biomarker exAGNx1 (NITEGE373 fragment from ADAMTS-mediated aggrecan degradation was measured on days 0, 5, 7, 10, 14, 19 and 21 of culture. The exAGNx1 levels increased in the cytokine-treated explant conditioned media, peaking at day 7: 24-fold for O+T group, 11-fold for IL-17A[25ng/ml] and 14-fold for IL-17A[100ng/ml] group when compared to the untreated group (Fig.4A). ExAGNx1 levels then decreased over the next two weeks but did not reach the levels of untreated group by the end of the tissue culture period (Fig.4A). Overall, the level of exAGNx1, calculated as area under the curve (AUC), was statistically significantly higher in both IL-17A groups and the positive control (O+T) group when compared to the untreated group (Fig. 4B).
As the collagen fibrillar network is a major component of the ECM, we also investigated the IL-17A effects on articular cartilage collagens by measuring biomarkers for MMP-mediated type II collagen (C2M) and type III collagen (C3M) degradation. The biomarkers were assessed in the conditioned media at days 0, 7, 10, 14, 19 and 21. Like with aggrecan degradation, the release of C2M fragment into the conditioned media increased over time in the cytokine-treated groups (Fig.4C) and the overall amount of the biomarker in the conditioned media was, on average, 6-fold higher in IL-17A[100ng/ml] explants, 3-fold higher in IL-17A[25ng/ml] explants, and 13-fold higher in O+T explants when compared to the untreated group, which was statistically significant (Fig.4D). Although C3M release into conditioned media also increased over time in the positive catabolic control O+T group and there was some induction observed in the IL-17[100ng/ml] group (1.9-fold increase at day 21) (Fig.4E), overall, there was no statistically significant C3M increase in the IL-17 groups when compared to the untreated group (Fig.4F).

The difference between exAGNx1 overall release (calculated as AUC) from 25ng/mL and 100ng/ml IL-17A-treated explants was not statistically significant (Mann-Whitney test, p=0.1782). Same was true for C2M release (Mann-Whitney test, p=0.0519).

**IL-17 induces MMP release from full depth bovine articular cartilage in our explant system**

To further confirm our biomarker results, conditioned media from days 0, 7, 14 and 21 were harvested and gelatinase release and activity were assessed by zymography (Fig.5). Pro-MMP9 was detected in all samples at day 7, with higher levels in O+T treated samples. At day 14, pro-MMP9 levels increased in the cytokine-treated groups but not in the control group. Additionally, the active MMP9 form was detected in O+T treatment group at day 14, and in both O+T and IL-17A[100ng/ml] groups at day 21, but not at day 14 or day 21 of the untreated group. Pro-MMP2 was detected in all samples at all timepoints except day 0, with increased levels in the O+T treatment group at day 21. The active MMP2 form was detected at day 14 and day 21 in all treatment groups, with the bands appearing more intense in the cytokine-treated groups at day 21.

**Proteomics identifies differentially expressed proteins upon IL-17 treatment**

To obtain an unbiased global protein release profile from the IL-17A-treated articular cartilage we
turned to proteomics. In brief, conditioned media from days 10, 14, 19 and 21 from two animals (two explants per each timepoint of each treatment group) was ethanol-precipitated to remove phenol red, trypsin-digested and analyzed by shotgun mass spectrometry. After protein identification and label-free quantification based on the top 3 most intense peptides for the protein group, the data was filtered so that only proteins present in all treatments, all timepoints, in both animals remained to obtain a data matrix with no missing values. This resulted in rejection of 175 proteins, and a final dataset of 199 proteins (Supplementary data) on which the differential expression analysis between untreated and IL-17A[100ng/ml] groups could be performed using ROTS statistics. 16 proteins were differentially expressed in the IL-17A vs untreated group with an FDR<0.05 (Fig.6A-B, Table 1). The upregulation of CHI3L1 in IL-17- and O+T- treated explant conditioned media was confirmed by Western blotting (Fig.7).

Discussion
We have shown that IL-17A can induce articular cartilage degradation in our bovine stifle joint full-depth cartilage explant model, as measured by proteoglycan degradation and cartilage turnover biomarker release. A remarkable GAG content reduction was observed in tissue at both lower and higher doses of IL-17A and there was a corresponding increase in GAG content in the conditioned media. This is in agreement with previous, shorter (up to 14 days) explant model studies, where stimulation of bovine nasal cartilage, or cartilage from bovine and porcine metacarpophalangeal or human knee joints with IL-17 led to a dose-response increase in nitric oxide production, increase in GAG release from tissue, and a decrease in matrix synthesis (39, 40, 51, 52). It was previously reported that IL-17 effects on GAG turnover were attenuated by aggrecanase inhibitor actinonin and that exposure of bovine articular cartilage explants to IL-17 upregulated ARGSV aggrecan fragment release (38). We confirm this finding by measuring an elevated NITEGE aggrecan fragment release from IL-17A-treated explants, which is the C-terminal neo-epitope of ADAMTS-mediated RNITEGE\(^{373}\)↓\(^{374}\)ARGSVIL cleavage in the G1 domain of aggrecan (45). We also find elevated ADAMTS5 levels in IL-17A explant media as compared to untreated in the mass spectrometry analysis (accession F1MRZ2). In contrast to the catabolic control (O+T), IL-17 appears to induce a milder, but prolonged
increase in the NITEGE degradation fragment release that continues above untreated levels at day 21 of culture.

In addition to aggrecan degradation, IL-17 stimulation of bovine nasal cartilage explant cultures previously had induced a type II collagen release into conditioned media, measured by a hydroxyproline assay at day 7 and day 14 of a 14-day culture, and upregulated the mRNA of MMP1, MMP3 and MMP13 (39). MMP3 was increased in our IL-17A explant conditioned media, confirming the upregulation of MMP3 at a protein level. We also see an increase in MMP9 release, which has not been previously shown in articular cartilage explants. Furthermore, we measure an increase in MMP-mediated type II collagen fragment (C2M) release in our IL-17A-treated explant conditioned media, definitively showing that at least some of the type II collagen release is MMP-mediated. The IL-17 induced type II collagen degradation occurs later than by O+T, thus in the future it may be worth extending the culture period to 4 weeks, considering a previous report that bovine explants were less responsive to IL-17 compared to porcine in terms of matrix breakdown (40) as well as our delayed C2M responses (compared to O+T). One reason could be the extended exAGNx1 observed, since it is suggested that aggrecan plays a protective role in preventing degradation of collagen fibrils (53). In addition to MMP-mediated type II collagen fragment release we also show an increase in MMP9 release (by zymography) in our IL-17-treated explant conditioned media. The MMP9-mediated type III collagen degradation fragment C3M release showed some induction in IL-17 [100ng/ml] explant group at the very last days of culture.

Previously, it has been shown by Western blotting and ELISA assays that in normal human chondrocytes IL-6 was upregulated in response to IL-17 through at least in part activation of MAP kinases and NFkB, and this upregulation was inhibited by dexamethasone (51, 54). We confirm this in our explant model and additionally find upregulation of CXCL6, CCL20 chemokines in IL-17A-treated explant conditioned media. CXCL6 and CCL20 gene expression has been previously reported significantly increased in IL-1β-treated human chondrocytes and CCL20 has also been reported to be abundantly expressed in OA cartilage sections (55, 56). CCL20 mRNA was shown to increase after chondrocyte (from healthy cartilage) stimulation with IL-6 or IL-17 and the treatment of normal,
healthy cartilage with CCL20 lead to an elevated proteoglycan release from the tissue (56). Other immune response mediators – complement factor B and SAA were also upregulated in IL-17A-treated explant conditioned media. Complement has a role in OA and factor B synthesis has been previously shown to be regulated by IL-17 in fibroblasts (57-60). Struglics et al. (2016) have shown that synovial fluid from OA joints contains substantial amounts of complement factors in comparison with the reference group (60). In OA cartilage, the release of ECM components and motifs (e.g. degradation products of type II collagen or other proteins) into the synovial fluid – the so-called damage-associated molecular patterns (DAMPs) – result from the dysregulated activity of various proteases; many of these pathways show interactions with complement factors (58, 59). Acute-phase SAA levels are elevated in OA and RA patient plasma and synovial fluid, and in OA increased SAA levels correlate positively with the Kellgren & Lawrence grade (61).

CHI3L1 (YKL-40), which was upregulated in the conditioned media of our IL-17A explant group, is also involved in joint pathology – its elevation in synovial fluid independently and positively related to WOMAC pain ($r = 0.531, p = 0.001$), physical disability ($r = 0.380, p = 0.025$), and total scores ($r = 0.407, p = 0.01$) in knee OA patients (62). CHI3L1 has also been previously shown to be released from OA cartilage, and its levels in the synovial fluid of OA patients have been reported to correlate positively with MMP1, MMP3, IL-6 and IL-17 (63). Additionally, its release from articular chondrocytes has been previously induced by other pro-inflammatory cytokines (e.g. IL-1, TNFα) and LPS, in the latter case through TLR4 and NFκB (64, 65). TLR4 activation is required for IL-17-induced multiple tissue inflammation in C57BL/6 mice, and TLR4 deficient DBA1J mice show decreased IL-17 levels and incidence of collagen-induced arthritis (66, 67).

**Study limitations**

We have chosen to work with bovine tissue due to the limited availability of healthy human tissue and have focused on stifle joint/knee articular cartilage, as this is the joint most commonly affected by OA. However, the bovine genome is not as well characterized as the human genome. For example, the primers for bovine IL-17 receptors were designed from predicted mRNA sequences, as verified sequences not yet exist. Ideally, the receptor expression should be further confirmed by histology or...
western blotting, however, no verified bovine IL-17 receptor specific antibodies are available. Additionally, there is limited availability of suitable antibodies to confirm proteomics results. We have used two IL-17 two concentrations, as it has been reported by Cai et al. (2001) that higher concentrations of IL-17 were required to elicit a NO and matrix breakdown response in bovine compared to porcine explants. In the future, it could be worth trying co-stimulation with other pro-inflammatory cytokines as, previously in bovine explants, IL-17 combination with TNFα resulted in synergy and, with LIF – in additive effect, respectively (39, 68).

The relatively low number of proteins (n=16) identified as statistically significant is in part due to the low power of this pilot study, and in part due to the strict filtering criteria, which omitted proteins with missing LFQ values. In the future, use of a Bayesian selection model could be tried out to reduce such data loss (69). Another major limitation of the study is that like the bovine genome, the bovine proteome is still relatively poorly characterized. UP000009136 contains multiple sequences per protein of varying annotation quality, with generally not that many reviewed proteins in SwissProt (n = 6006) when compared to human (n = 20402).

Conclusions
To summarize, IL-17A can induce articular cartilage degradation in our bovine full-depth explant model. Compared to previous studies, our model brings value in the extended tissue culture - previously in literature the duration of the IL-17 ex-vivo models were limited to 14 days. We also take more frequent measurements (every 2-3 days instead of every 7 days of the 14-day study), which gives a better overview of the undergoing processes. The exAGNx1 biomarker, and potentially also C2M if the culture period would be extended to four weeks, appear to be good tools for assessing cartilage damage in this model. Finally, the confirmation of previously published findings supports the validity of the model as a tool for IL-17 mediated cartilage catabolism exploration by mass spectrometry, and for cartilage degradation biomarker discovery. The model will allow us to further study protein cleavages and to time-profile the IL-17-induced articular cartilage degradome, as well as to look for neo-epitopes specific for IL-17-mediated articular cartilage degradation.

List Of Abbreviations
ADAMTS – A Disintegrin And Metalloproteinase with Thrombospondin Motifs

BEX – Full-Depth Bovine Articular Cartilage Explants

COX-2 – Cyclooxygenase 2

DAMPs – Damage-Associated Molecular Patterns

DMMB – Dimethyl Methylene Blue

DMOAD – Disease-Modifying Osteoarthritis Drug

ECM – Extracellular Matrix

ELISA – Enzyme-Linked Immunosorbent Assay

EMA – European Medical Agency

FDA – Federal Drug Administration

GAG – Glycosaminoglycan

IL-17 – Interleukin-17

IL-17R – Interleukin-17 Receptor

IL-6 – Interleukin-6

LLMR – Lower Limit of Measurement Range

MAPK – Mitogen-Activated Protein Kinase

MMP – Matrix Metalloproteinase

NFκB – Nuclear Factor Kappa Light Chain Enhancer of Activated B Cells

NO – Nitric Oxide

OA – Osteoarthritis

OSM – Oncostatin M

PGE₂ – Prostaglandins

RA – Rheumatoid Arthritis

TBST – Tris-buffered saline, 0.1% Tween 20

TMB – 3,3',5,5'-Tetramethylbenzidine

TNFα – Tumor Necrosis Factor Alpha

ULMR – Upper Limit of Measurement Range
Declarations

Ethics approval and consent to participate

Permission (J.nr.: 2015-12-711-03228/AMSE) to use animal by-products (category 3) for research and diagnostics from the Danish Veterinary and Food Administration under Ministry of Environment and Food of Denmark. Approval number (Danish: Godkendelsesnummer): DK-10-3-oth-005.

Consent for publication

Not applicable.

Availability of data and material

The raw data used and/or analyzed during the current study could not be deposited in a public repository, but are available from the corresponding author or senior authors on request after establishment of a research agreement.

Competing interests

DS is an industrial PhD student – enrolled at Lund University, employed by Nordic Bioscience. ACBJ and YH are full-time employees at Nordic Bioscience, which is a privately owned, small-medium size enterprise (SME) partly focused on the development of biomarkers for rheumatic and fibrotic diseases. ACBJ is a shareholder of Nordic Bioscience. AA and PÖ have no competing interests.

Funding

The study was supported by an industrial PhD scholarship grant (ID15-0035) from Swedish Strategic Research Foundation (SSF) – recipients PÖ and ACBJ. The MS instrument was funded by IngaBritt and Arne Lundbergs Research Foundation – grant number 425, recipient: PÖ.

Authors' contributions

The individual contributions of each author were as follows: DS – design, data acquisition, analysis, interpretation of the study and drafting and revision of the manuscript. ACBJ: conception, design, analysis, interpretation of the study, and substantive revision of the manuscript. PÖ: conception, design, acquisition, interpretation of the study, and substantive revision of the manuscript. AA: design, interpretation of the study, and substantive revision of the manuscript. YH: design of the study. DS, ACBJ, PÖ, YH, AA have all approved the submitted version (and any substantially modified
version that involves the author's contribution to the study) and agreed both to be personally accountable for the author's own contributions and to ensure that questions related to the accuracy or integrity of any part of the work, even ones in which the author was not personally involved, are appropriately investigated, resolved, and the resolution documented in the literature.

ACKNOWLEDGEMENTS

A special thank you to Neserin Ali (Lund University), Cecilie Bager and Joseph Blair (ProScion, Nordic Bioscience) for their invaluable help with the MS data analysis.

References

1. Bhosale AM, Richardson JB. Articular cartilage: structure, injuries and review of management. British Medical Bulletin. 2008;87(1):77-95.
2. Goldring MB, Marcu KB. Cartilage homeostasis in health and rheumatic diseases. Arthritis research & therapy. 2009;11(3):224-.
3. Litwic A, Edwards MH, Dennison EM, Cooper C. Epidemiology and burden of osteoarthritis. Br Med Bull. 2013;105:185-99.
4. Van Spil WE, Kubassova O, Boesen M, Bay-Jensen AC, Mobasher A. Osteoarthritis phenotypes and novel therapeutic targets. Biochem Pharmacol. 2019.
5. Ackerman IN, Graves SE, Wicks IP, Bennell KL, Osborne RH. Severely compromised quality of life in women and those of lower socioeconomic status waiting for joint replacement surgery. Arthritis Rheum. 2005;53(5):653-8.
6. Ackerman IN, Ademi Z, Osborne RH, Liew D. Comparison of health-related quality of life, work status, and health care utilization and costs according to hip and knee joint disease severity: a national Australian study. Phys Ther. 2013;93(7):889-99.
7. Mandl LA. Osteoarthritis year in review 2018: clinical. Osteoarthritis Cartilage. 2019;27(3):359-64.
8. Livshits G, Kalinkovich A. Hierarchical, imbalanced pro-inflammatory cytokine networks govern the pathogenesis of chronic arthropathies. Osteoarthritis Cartilage.
9. Houard X, Goldring MB, Berenbaum F. Homeostatic mechanisms in articular cartilage and role of inflammation in osteoarthritis. Current rheumatology reports. 2013;15(11):375-.

10. Goldberg M, Nadiv O, Luknar-Gabor N, Agar G, Beer Y, Katz Y. Synergism between tumor necrosis factor alpha and interleukin-17 to induce IL-23 p19 expression in fibroblast-like synoviocytes. Mol Immunol. 2009;46(8-9):1854-9.

11. Katz Y, Nadiv O, Beer Y. Interleukin-17 enhances tumor necrosis factor alpha-induced synthesis of interleukins 1,6, and 8 in skin and synovial fibroblasts: a possible role as a "fine-tuning cytokine" in inflammation processes. Arthritis Rheum. 2001;44(9):2176-84.

12. LeGrand A, Fermor B, Fink C, Pisetsky DS, Weinberg JB, Vail TP, et al. Interleukin-1, tumor necrosis factor alpha, and interleukin-17 synergistically up-regulate nitric oxide and prostaglandin E2 production in explants of human osteoarthritic knee menisci. Arthritis Rheum. 2001;44(9):2078-83.

13. Koenders MI, Marijnissen RJ, Devesa I, Lubberts E, Joosten LA, Roth J, et al. Tumor necrosis factor-interleukin-17 interplay induces S100A8, interleukin-1beta, and matrix metalloproteinases, and drives irreversible cartilage destruction in murine arthritis: rationale for combination treatment during arthritis. Arthritis Rheum. 2011;63(8):2329-39.

14. Sandy JDD, Chan DDD, Trevino RLL, Wimmer MAA, Plaas A. Human genome-wide expression analysis reorients the study of inflammatory mediators and biomechanics in osteoarthritis. Osteoarthritis and Cartilage. 2015;23(11):1939-45.

15. Moseley TA, Haudenschild DR, Rose L, Reddi AH. Interleukin-17 family and IL-17 receptors. Cytokine & Growth Factor Reviews. 2003;14:155-74.
16. Gaffen SL. An overview of IL-17 function and signaling. Cytokine. 2008;43(3):402-7.
17. Sønder SU, Saret S, Tang W, Sturdevant DE, Porcella SF, Siebenlist U. IL-17-induced NF-kappaB activation via CIKS/Act1: physiologic significance and signaling mechanisms. The Journal of biological chemistry. 2011;286(15):12881-90.
18. Liu S, Song X, Chrunyk BA, Shanker S, Hoth LR, Marr ES, et al. Crystal structures of interleukin 17A and its complex with IL-17 receptor A. Nature Communications. 2013;4(1):1888-.
19. Goepfert A, Lehmann S, Wirth E, Rondeau J-M. The human IL-17A/F heterodimer: a two-faced cytokine with unique receptor recognition properties. Scientific Reports. 2017;7(1):8906-.
20. Honorati MC, Meliconi R, Pulsatelli L, Cane S, Frizzerio L, Facchini A. High in vivo expression of interleukin-17 receptor in synovial endothelial cells and chondrocytes from arthritis patients. Rheumatology (Oxford). 2001;40(5):522-7.
21. Chabaud M, Lubberts E, Joosten L, van Den Berg W, Miossec P. IL-17 derived from juxta-articular bone and synovium contributes to joint degradation in rheumatoid arthritis. Arthritis Res. 2001;3(3):168-77.
22. Chyuan IT, Chen J-Y. Role of Interleukin- (IL-) 17 in the Pathogenesis and Targeted Therapies in Spondyloarthropathies. Mediators of inflammation. 2018;2018:2403935-.
23. Kampylafka E, d'Oliveira I, Linz C, Lerchen V, Stemmler F, Simon D, et al. Resolution of synovitis and arrest of catabolic and anabolic bone changes in patients with psoriatic arthritis by IL-17A blockade with secukinumab: results from the prospective PSARTROS study. Arthritis Res Ther. 2018;20(1):153.
24. Chen B, Deng Y, Tan Y, Qin J, Chen L-B. Association between severity of knee osteoarthritis and serum and synovial fluid interleukin 17 concentrations. The Journal of International Medical Research. 2014;42(1):138-44.
25. Teunis T, Beekhuizen M, Van Osch GVM, Schuurman AH, Creemers LB, van Minnen LP. Soluble mediators in posttraumatic wrist and primary knee osteoarthritis. The archives of bone and joint surgery. 2014;2(3):146-50.

26. Liu Y, Peng HDE, Meng ZFG, Wei M, Liu Abc Y, Peng HDE, et al. Correlation of IL-17 Level in Synovia and Severity of Knee Osteoarthritis. Medical science monitor : international medical journal of experimental and clinical research. 2015;21:1732-6.

27. Wang K, Xu J, Cai J, Zheng S, Han W, Antony B, et al. Serum levels of interleukin-17 and adiponectin are associated with infrapatellar fat pad volume and signal intensity alteration in patients with knee osteoarthritis. Arthritis Res Ther. 2016;18:193.

28. Snelling SJB, Bas S, Puskas GJ, Dakin SG, Suva D, Finckh A, et al. Presence of IL-17 in synovial fluid identifies a potential inflammatory osteoarthritic phenotype. 2017:1-13.

29. Wang K, Xu J, Cai J, Zheng S, Yang X, Ding C. Serum levels of resistin and interleukin-17 are associated with increased cartilage defects and bone marrow lesions in patients with knee osteoarthritis. Mod Rheumatol. 2017;27(2):339-44.

30. Han L, Lee HS, Yoon JH, Choi WS, Park YG, Nam SW, et al. Association of IL-17A and IL-17F single nucleotide polymorphisms with susceptibility to osteoarthritis in a Korean population. Gene. 2014;533(1):119-22.

31. Karsdal MA, Christiansen C, Ladel C, Henriksen K, Kraus VB, Bay-Jensen AC. Osteoarthritis - a case for personalized health care? Osteoarthritis and Cartilage. 2014;22(1):7-16.

32. Kjelgaard-Petersen CF, Platt A, Braddock M, Jenkins MA, Musa K, Graham E, et al. Translational Biomarkers and Ex Vivo Models of Joint Tissues as a Tool for Drug Development in Rheumatoid Arthritis. Arthritis Rheumatol. 2018;70(9):1419-28.

33. Wu J, Liu W, Bemis A, Wang E, Qiu Y, Morris EA, et al. Comparative proteomic
characterization of articular cartilage tissue from normal donors and patients with osteoarthritis. Arthritis Rheum. 2007;56(11):3675-84.

34. Hosseini S, Onnerfjord P, Dahlberg LE. Targeted proteomics of hip articular cartilage in OA and fracture patients. J Orthop Res. 2019;37(1):131-5.

35. Balakrishnan L, Nirujogi RS, Ahmad S, Bhattacharjee M, Manda SS, Renuse S, et al. Proteomic analysis of human osteoarthritis synovial fluid. Clin Proteomics. 2014;11(1):6.

36. de Seny D, Sharif M, Fillet M, Cobraiville G, Meuwis MA, Maree R, et al. Discovery and biochemical characterisation of four novel biomarkers for osteoarthritis. Ann Rheum Dis. 2011;70(6):1144-52.

37. Rampersad SN. Multiple applications of Alamar Blue as an indicator of metabolic function and cellular health in cell viability bioassays. Sensors (Basel). 2012;12(9):12347-60.

38. Cai L, Yin J, Starovasnik MA, Hogue DA, Hillan KJ, Mort JS, et al. PATHWAYS BY WHICH INTERLEUKIN 17 INDUCES ARTICULAR CARTILAGE BREAKDOWN IN VITRO AND IN VIVO. 2001.

39. Koshy PJ, Henderson N, Logan C, Life PF, Cawston TE, Rowan AD, et al. Interleukin 17 induces cartilage collagen breakdown: novel synergistic effects in combination with proinflammatory cytokines. Annals of the rheumatic diseases. 2002;61(8):704-13.

40. Cai L, Suboc P, Hogue DA, Fei DTW, Filvaroff EH. Interleukin 17 induced nitric oxide suppresses matrix synthesis and protects cartilage from matrix breakdown. The Journal of rheumatology. 2002;29(8):1725-36.

41. Farndale RW, Buttle DJ, Barrett AJ. Improved quantitation and discrimination of sulphated glycosaminoglycans by use of dimethylmethylen blue. Biochim Biophys Acta. 1986;883(2):173-7.
42. Mort JS, Roughley PJ. Measurement of glycosaminoglycan release from cartilage explants. Methods Mol Med. 2007;135:201-9.

43. Barascuk N, Veidal SS, Larsen L, Larsen DV, Larsen MR, Wang J, et al. A novel assay for extracellular matrix remodeling associated with liver fibrosis: An enzyme-linked immunosorbent assay (ELISA) for a MMP-9 proteolytically revealed neo-epitope of type III collagen. Clin Biochem. 2010;43(10-11):899-904.

44. Bay-Jensen AC, Liu Q, Byrjalsen I, Li Y, Wang J, Pedersen C, et al. Enzyme-linked immunosorbent assay (ELISAs) for metalloproteinase derived type II collagen neoepitope, CIIM--increased serum CIIM in subjects with severe radiographic osteoarthritis. Clin Biochem. 2011;44(5-6):423-9.

45. Wang B, Chen P, Jensen AC, Karsdal MA, Madsen SH, Sondergaard BC, et al. Suppression of MMP activity in bovine cartilage explants cultures has little if any effect on the release of aggrecanase-derived aggrecan fragments. BMC Res Notes. 2009;2:259.

46. Folkesson E, Turkiewicz A, Englund M, Onnerfjord P. Differential protein expression in human knee articular cartilage and medial meniscus using two different proteomic methods: a pilot analysis. BMC Musculoskelet Disord. 2018;19(1):416.

47. Seyednasrollah F, Rantanen K, Jaakkola P, Elo LL. ROTS: reproducible RNA-seq biomarker detector-prognostic markers for clear cell renal cell cancer. Nucleic Acids Res. 2016;44(1):e1.

48. Suomi T, Seyednasrollah F, Jaakkola MK, Faux T, Elo LL. ROTS: An R package for reproducibility-optimized statistical testing. PLoS Comput Biol. 2017;13(5):e1005562.

49. Elo LL, Hiissa J, Tuimala J, Kallio A, Korpelainen E, Aittokallio T. Optimized detection of differential expression in global profiling experiments: case studies in clinical transcriptomic and quantitative proteomic datasets. Brief Bioinform. 2009;10(5):547-
50. Elo LL, Filen S, Lahesmaa R, Aittokallio T. Reproducibility-optimized test statistic for ranking genes in microarray studies. IEEE/ACM Trans Comput Biol Bioinform. 2008;5(3):423-31.

51. Hymowitz SG, Filvaroff EH, Yin JP, Lee J, Cai L, Risser P, et al. IL-17s adopt a cystine knot fold: structure and activity of a novel cytokine, IL-17F, and implications for receptor binding. The EMBO journal. 2001;20(19):5332-41.

52. Attur MG, Patel RN, Abramson SB, Amin AR. Interleukin-17 up-regulation of nitric oxide production in human osteoarthritis cartilage. Arthritis & Rheumatism. 1997;40(6):1050-3.

53. Pratta MA, Yao W, Decicco C, Tortorella MD, Liu RQ, Copeland RA, et al. Aggrecan protects cartilage collagen from proteolytic cleavage. J Biol Chem. 2003;278(46):45539-45.

54. Shalom-Barak T, Quach J, Lotz M. Interleukin-17-induced gene expression in articular chondrocytes is associated with activation of mitogen-activated protein kinases and NF-kappaB. J Biol Chem. 1998;273(42):27467-73.

55. Sandell LJ, Xing X, Franz C, Davies S, Chang LW, Patra D. Exuberant expression of chemokine genes by adult human articular chondrocytes in response to IL-1beta. Osteoarthritis Cartilage. 2008;16(12):1560-71.

56. Alaaeddine N, Antoniou J, Moussa M, Hilal G, Kreichaty G, Ghanem I, et al. The chemokine CCL20 induces proinflammatory and matrix degradative responses in cartilage. Inflamm Res. 2015;64(9):721-31.

57. Katz Y, Nadiv O, Rapoport MJ, Loos M. IL-17 regulates gene expression and protein synthesis of the complement system, C3 and factor B, in skin fibroblasts. Clin Exp Immunol. 2000;120(1):22-9.
58. Orlowsky EW, Kraus VB. The role of innate immunity in osteoarthritis: when our first line of defense goes on the offensive. J Rheumatol. 2015;42(3):363-71.

59. Silawal S, Triebel J, Bertsch T, Schulze-Tanzil G. Osteoarthritis and the Complement Cascade. Clin Med Insights Arthritis Musculoskelet Disord. 2018;11:1179544117751430.

60. Struglics A, Okroj M, Sward P, Frobell R, Saxne T, Lohmander LS, et al. The complement system is activated in synovial fluid from subjects with knee injury and from patients with osteoarthritis. Arthritis Res Ther. 2016;18(1):223.

61. de Seny D, Cobraiville G, Charlier E, Neuville S, Esser N, Malaise D, et al. Acute-phase serum amyloid a in osteoarthritis: regulatory mechanism and proinflammatory properties. PLoS One. 2013;8(6):e66769.

62. Guan J, Liu Z, Li F, Feng JS, Wang HJ, Chu JG, et al. Increased Synovial Fluid YKL-40 Levels are Linked with Symptomatic Severity in Knee Osteoarthritis Patients. Clin Lab. 2015;61(8):991-7.

63. Vaananen T, Koskinen A, Paukkeri EL, Hamalainen M, Moilanen T, Moilanen E, et al. YKL-40 as a novel factor associated with inflammation and catabolic mechanisms in osteoarthritic joints. Mediators Inflamm. 2014;2014:215140.

64. Recklies AD, Ling H, White C, Bernier SM. Inflammatory cytokines induce production of CHI3L1 by articular chondrocytes. J Biol Chem. 2005;280(50):41213-21.

65. Haglund L, Bernier SM, Onnerfjord P, Recklies AD. Proteomic analysis of the LPS-induced stress response in rat chondrocytes reveals induction of innate immune response components in articular cartilage. Matrix Biol. 2008;27(2):107-18.

66. Tang H, Pang S, Wang M, Xiao X, Rong Y, Wang H, et al. TLR4 activation is required for IL-17-induced multiple tissue inflammation and wasting in mice. J Immunol. 2010;185(4):2563-9.
67. Pierer M, Wagner U, Rossol M, Ibrahim S. Toll-like receptor 4 is involved in inflammatory and joint destructive pathways in collagen-induced arthritis in DBA1J mice. PLoS One. 2011;6(8):e23539.

68. Martel-Pelletier J, Mineau Fo, Jovanovic D, Di Battista JA, Pelletier J-P. Mitogen-activated protein kinase and nuclear factor ?B together regulate interleukin-17-induced nitric oxide production in human osteoarthritic chondrocytes: Possible role of transactivating factor mitogen-activated protein kinase-activated protein kinase (MAPKAPK). Arthritis & Rheumatism. 1999;42(11):2399-409.

69. O'Brien JJ, Gunawardena HP, Paulo JA, Chen X, Ibrahim JG, Gygi SP, et al. The effects of nonignorable missing data on label-free mass spectrometry proteomics experiments. Ann Appl Stat. 2018;12(4):2075-95.

Table
Table 1 Proteins upregulated in the conditioned media of IL-17A [100 ng/ml] samples when compared to untreated (adjusted p-value <0.05)
| Accession | Description                                      | Gene   | ROTS-statistic | P-value       | FD R |
|-----------|--------------------------------------------------|--------|----------------|---------------|-----|
| Q8SQB1    | C-C motif chemokine 20                           | CCL20  | -75.25005      | 0.001595477   | 0   |
| Q8SQ28    | Serum amyloid A protein                          | SAA3   | -75.1999       | 0.003190955   | 0   |
| G3X7D2    | Chitinase-3-like protein 1                       | CHI3L1 | -70.16214      | 0.004786432   | 0   |
| P80221    | C-X-C motif chemokine 6                          | CXCL6  | -69.4439       | 0.00638191    | 0   |
| F1MF86    | Latent-transforming growth factor beta-binding protein 2 | LTBP2 | -68.0478      | 0.007977387   | 0   |
| F1MRZ2    | A disintegrin and metalloproteinase with thrombospondin motifs 5 | ADAMTS5 | -63.8272      | 0.009572864   | 0   |
| F1MTX6    | Matrix metalloproteinase                         | MMP3   | -61.13251      | 0.011168342   | 0   |
| P81187    | Complement factor B                              | CFB    | -60.51259      | 0.012763819   | 0   |
| F1MXR3    | ADAMTS like 4                                    | ADAMTSL4 | -59.54655  | 0.014359296   | 0   |
| Q5GN72    | Alpha-1-acid glycoprotein                        | AGP    | -56.24703      | 0.015954774   | 0   |
| F1MD77    | Laminin subunit gamma 1                          | LAMC1  | -54.46369      | 0.017550251   | 0   |
| E1BKX7    | Filamin B                                        | FLNB   | -54.19423      | 0.019145729   | 0   |
| P33072    | Protein-lysine 6-oxidase                         | LOX    | -50.86677      | 0.020741206   | 0   |
| Q58CQ9    | Pantetheinase                                     | VNN1   | -50.70812      | 0.022336683   | 0   |
| P26892    | Interleukin-6                                    | IL6    | -50.11704      | 0.023932161   | 0   |
| Q6B411    | Lysozyme C, milk isozyme                         | LYZ    | -45.56671      | 0.025527638   | 0   |

**Supplementary Figure Legend**

**Supplementary Figure 1** | Dose-response test of bovine articular cartilage explants (BEX) by
assessing MMP-mediated type II collagen degradation on day 14 of bovine explant culture. Data from 1 cow, 6 individually cultured explants per each treatment. ULMR denotes the upper measurement limit of the assay.

Figures

![Figure 1](image)

IL-17 receptor expression analysis in bovine articular cartilage by PCR and agarose gel (2%) electrophoresis. mRNA was extracted from the cartilage tissue of two animals, obtained within 48 hours after slaughter, reverse-transcribed to cDNA, and 0.5 ng of template cDNA was amplified with IL-17 receptor primers. In both animals, PCR products for IL-17RA (lanes labeled A, expected size 459 bp) and IL-17RC (lanes C, expected size 178 bp) were observed. Additionally, PCR products for IL-17RD (lanes D, expected 364 or 433 bp) were also observed, albeit very weak in animal 2. Lanes are labeled with letters denoting the IL17R variant amplified and bands corresponding to the expected product sizes are indicated with white arrowheads.
Figure 2

AlamarBlue® metabolic activity assessment of the bovine articular cartilage explants over a three-week culture period. A) Metabolic activity, reported as a fluorescence (590-540 nm) readout, at day 0, 7, 14 and 21 in conditioned media from untreated BEX explants, or BEX explants treated with OSM [10 ng/mL] + TNFα [20 ng/mL], or IL-17A [100 ng/ml or 25 ng/ml]. B) Area under the curve (AUC) was calculated from each explant’s fluorescence readout over time. Data is presented as means; bars represent SD and ns indicates no statistically significant difference between either one of the treatment groups compared to the untreated group (Kruskall-Wallis test with Dunn’s post-hoc test for multiple comparisons where p < 0.05 was considered significant).
Glycosaminoglycan content in conditioned media and explant tissue. A) GAG release into conditioned media over a 3-week culture period as measured by a DMMB assay; data is represented as a fold-change to untreated. B) Cumulative release of GAG into the medium over the entire culture period, determined as the AUC calculated from each explant’s GAG release over time. Asterisks (*) represent statistical significance level compared to untreated: ***P<0.001. C) Safranin O/Fast green staining of bovine full-depth articular cartilage explants on the final day of tissue culture in the presence or absence of pro-inflammatory cytokines (magnification: 10×, scale bar: 200 μm). Note the pronounced loss of proteoglycan (red Safranin O staining) in cytokine-treated explants compared to the
untreated explants.

Figure 4

Cartilage ECM turnover serological biomarker release into explant conditioned media. The full-depth bovine articular cartilage explants were cultured either in absence (untreated), or in the presence of a catabolic stimuli: OSM [10 ng/ml] + TNFα [20 ng/ml], or IL-17A [100 ng/ml, 25 ng/ml] for 21 days with conditioned media exchanged three times a week. A) ADAMTS-mediated aggrecan degradation fragment exAGNx1 release into conditioned media measured at day 0, 5, 7, 10, 14, 19 and 21 represented as fold-change to untreated. B) AUC, as an indication of total signal, was calculated from each explant’s AGNx1 release over time. C) MMP-mediated type II collagen degradation fragment C2M release into conditioned media measured at day 0, 7, 10, 14, 19 and 21 represented as fold-change to untreated. D) AUC, as an indication of total signal, was calculated from each explant’s C2M release over time. E) MMP-mediated type III collagen degradation fragment C3M release into conditioned media measured at day 0, 5, 7, 10, 14, 19 and 21 represented as fold-change to untreated.
media measured at day 0, 7, 10, 14, 19 and 21 represented as fold-change to untreated. D) AUC, as an indication of total signal, was calculated from each explant’s C3M release over time. Asterisks (*) represent statistical significance level compared to untreated: *P<0.05; ***P<0.001.

Figure 5

Gelatin zymography assessment of MMP2 and MMP9 release from bovine articular cartilage explants. Conditioned media from two explants for each condition from two separate animals were analyzed at days 0, 7, 14 and 21. Pro-MMP9 (~92 kDa), active MMP9 (~82 kDa), pro-MMP2 (~72 kDa), cleaved MMP2 (~63 kDa) are indicated with arrows.
Differential expression analysis of proteins released into BEX conditioned media. Conditioned media from days 10, 14, 19 and 21 was analyzed and relatively quantified by mass spectrometry. AUC was calculated as an indication of total signal, and untreated and IL-17A treatment group AUC values were compared using ROTS statistical test with FDR<0.05 considered significant. Only proteins with relative abundance values in both treatment groups were considered. A) a volcano plot showing the relationship between fold changes and p-values, and B) a heatmap with hierarchical clustering showing the expression levels of the 16 differentially expressed proteins as colors.
Figure 7

CHI3L1 release into BEX conditioned media in response to cytokine treatment in explants from two independent animals. Conditioned media from control or cytokine-treated (IL-17A [100 ng/ml] or OSM [10 ng/ml] + TNFα [20 ng/ml]) explants, from days 10, 14, 19 and 21 was pooled and the same volume of pooled media (20 µl) was analyzed by Western blotting. Numbers 1 and 2 in the figure denote the two animals. An intense band, that corresponds to CHI3L1 (MW: 39 kDa), was observed in the 100 ng/ml of IL-17A as well as the O+T groups.

Supplementary Files
This is a list of supplementary files associated with this preprint. Click to download.

BMC_Supplementary_data.xlsx
BMC_SuppFig_1.pdf